A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma CARTITUDE-2

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506587-13-00

Enrollment

Registered

2024-03-06

Start date

2020-01-30

Completion date

Unknown

Last updated

2025-09-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Brief summary

MRD negative rate (10-5 threshold) as defined by the International Myeloma Working Group (IMWG) criteria using next generation sequencing (NGS) or next generation flow (NGF)

Interventions

DRUGJNJ-54767414

DRUGLenalidomide Accord 25 mg hard capsules

DRUGLenalidomide Accord 5 mg hard capsules

DRUGLenalidomide Accord 20 mg hard capsules

DRUGDexamethasone Tablets BP 2.0mg

DRUGFLUDARABINE

DRUGVELCADE 3.5 mg powder for solution for injection

DRUGLenalidomide Accord 15 mg hard capsules

DRUGJNJ-68284528

DRUGLenalidomide Accord 10 mg hard capsules

DRUGDexamethason 4 mg JENAPHARM®

DRUGEndoxana Injection 1000 mg Powder for Solution for Injection

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
MRD negative rate (10-5 threshold) as defined by the International Myeloma Working Group (IMWG) criteria using next generation sequencing (NGS) or next generation flow (NGF)	—

Countries

Belgium, France, Germany, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026